Opportunity
Platinum-based anticancer drugs, such as cisplatin, have been widely used in clinical oncology for decades. However, these drugs face significant challenges, including severe toxic side effects (e.g., nephrotoxicity, neurotoxicity) and the emergence of drug resistance in cancer cells. Cisplatin-resistant cancers, particularly ovarian, lung, and breast cancers, often relapse after initial treatment, leading to poor patient outcomes. The limitations of existing platinum therapies create a pressing need for novel compounds that can overcome resistance mechanisms while minimizing toxicity. This patent addresses these challenges by introducing innovative platinum complexes with enhanced efficacy against resistant cancer cell lines and improved safety profiles.
Technology
The invention discloses novel phosphine-coordinated platinum complexes with a unique chemical structure (Structure II), where tailored ligands (e.g., substituted aryl or alkyl groups) modulate the compound’s reactivity and bioavailability. Key innovations include:
- Structural Design: The complexes feature customizable R-groups (e.g., phenyl, methyl, carboxyl) that optimize binding to cancer cell targets while reducing off-target effects.
- Enhanced Efficacy: These compounds demonstrate superior cytotoxicity against cisplatin-resistant cell lines (e.g., A2780CisR, A549CisR) compared to traditional platinum drugs, as evidenced by low IC50 values in vitro.
- Synthetic Flexibility: The preparation method allows for modular ligand substitution, enabling fine-tuning of pharmacokinetic properties. For example, complexes with chelating phosphine ligands (e.g., Structure III/IV) exhibit improved stability and tumor targeting.
Advantages
- Overcomes Drug Resistance: Effective against cisplatin-resistant cancers (e.g., ovarian, lung).
- Reduced Toxicity: Designed to minimize side effects through selective targeting.
- Structural Versatility: Modular synthesis supports diverse therapeutic applications.
- High Potency: Some complexes (e.g., 3b) show IC50 values as low as 0.07 µM, surpassing cisplatin.
Application
- Oncology: Treatment of ovarian, lung, and breast cancers, including resistant variants.
- Pharmaceuticals: Formulated as injectable or oral dosage forms for chemotherapy.
- Research Tools: Used to study mechanisms of platinum resistance and apoptosis.
